(MENAFN- Gulf Times) German biotech company CureVac said on Friday its potential vaccine against the coronavirus induced an immune response in pre-clinical animal studies.
CureVac said the potential vaccine, known as CVnCoV, produced neutralising antibodies and activated T-cells in hamsters and mice.
The vaccine, which is being tested in humans in early and mid-stage trials, also protected the lungs of hamsters when they were exposed to a live virus, the company said.
"The pre-clinical data published today show that our Covid-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defence and providing lung protection in a relevant challenge model, said CureVac Chief Technology Officer Mariola Fotin-Mleczek.
MENAFN2310202000670000ID1101007058
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.